[1]李晓丽,任少辉,李雅然,等.递增降尿酸药物预防和减少痛风急性发作的疗效及安全性评估[J].医学信息,2022,35(18):30-33.[doi:10.3969/j.issn.1006-1959.2022.18.007]
 LI Xiao-li,REN Shao-hui,LI Ya-ran,et al.Efficacy and Safety Evaluation of Increasing Uric Acid Lowering Drugs to Prevent and Reduce Acute Gout Attacks[J].Journal of Medical Information,2022,35(18):30-33.[doi:10.3969/j.issn.1006-1959.2022.18.007]
点击复制

递增降尿酸药物预防和减少痛风急性发作的疗效及安全性评估()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年18期
页码:
30-33
栏目:
论著
出版日期:
2022-09-15

文章信息/Info

Title:
Efficacy and Safety Evaluation of Increasing Uric Acid Lowering Drugs to Prevent and Reduce Acute Gout Attacks
文章编号:
1006-1959(2022)18-0030-04
作者:
李晓丽任少辉李雅然
(邢台市人民医院风湿免疫科,河北 邢台 054000)
Author(s):
LI Xiao-liREN Shao-huiLI Ya-ranet al.
(Department of Rheumatology,Xingtai People’s Hospital,Xingtai 054000,Hebei,China)
关键词:
痛风急性发作非布司他秋水仙碱
Keywords:
Acute gout attackFebuxostatColchicine
分类号:
R684.3
DOI:
10.3969/j.issn.1006-1959.2022.18.007
文献标志码:
A
摘要:
目的 研究在起始降尿酸阶段逐步递增降尿酸药物非布司他剂量预防和减少痛风急性发作的疗效及安全性。方法 选取2018年8月-2020年6月我院门诊或住院的痛风患者102例,随机分为试验组(54例)和对照组(48例)。对照组采用非布司他(40 mg/d)联合秋水仙碱(0.5mg/d,12周)治疗,试验组采用递增非布司他治疗,剂量从10 mg/d(4周)、20 mg/d(4周)到40 mg/d(4周)。比较两组治疗12周时痛风急性发作情况、血清尿酸达标率及不良反应发生情况。结果 治疗12周时试验组和对照组痛风急性发作频率分别为20.37%、18.75%,差异无统计学意义(P>0.05);试验组和对照组血清尿酸达标率分别为81.48%、83.33%,差异无统计学意义(P>0.05);治疗期间,两组均无严重不良事件发生。结论 逐步递增降尿酸药物非布司他剂量可有效预防痛风急性发作,可能成为低剂量秋水仙碱预防急性发作的有效替代方案。
Abstract:
Objectives To study the efficacy and safety of gradually increasing the dose of febuxostat in the initial stage of uric acid lowering to prevent and reduce the acute attack of gout.Methods A total of 102 outpatients or inpatients with gout in our hospital from August 2018 to June 2020 were selected and randomly divided into an experimental group (54 cases) and a control group (48 cases). The control group was treated with febuxostat (40 mg/d) combined with colchicine (0.5 mg/d, 12 weeks). The experimental group was treated with increasing doses of febuxostat from 10 mg/d (4 weeks), 20 mg/d (4 weeks) to 40 mg/d (4 weeks). The acute attack of gout, serum uric acid compliance rate and adverse reactions were compared between the two groups at 12 weeks of treatment.Results At 12 weeks of treatment, the incidence of acute gout attack in the experimental group and the control group was 20.37% and 18.75%, respectively, and the difference was not statistically significant (P>0.05). The serum uric acid compliance rates of the experimental group and the control group were 81.48% and 83.33%, respectively, and the difference was not statistically significant (P>0.05). During the treatment, no serious adverse events occurred in both groups.Conclusion The gradually increasing dose of uric acid-lowering drug febuxostat can effectively prevent the acute attack of gout, which may become an effective alternative to low-dose colchicine to prevent acute attack.

参考文献/References:

[1]Richette P,Doherty M,Pascual E,et al.2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout[J].Ann Rheum Dis,2020,79(1):31-38.[2]Kumar M,Manley N,Mikuls TR.Gout Flare Burden, Diagnosis, and Management: Navigating Care in Older Patients with Comorbidity[J].Drugs & Aging,2021,38(7):545-557. [3]Singh JA.Disease modification in gout: a qualitative study of gout expert rheumatologists[J].Rheumatol Adv Pract,2022,6(1):rkab107.[4]Richette P,Doherty M,Pascual E,et al.2016 updated EULAR evidence-based recommendations for the management of gout[J].Ann Rheum Dis,2017,76:29-42.[5]McKenzie BJ,Wechalekar MD,Johnston RV,et al.Colchicine for acute gout[J].Cochrane Database Syst Rev,2021,8(8):CD006190. [6]Cozza J,Do TVC,Ganti S,et al.The Ugly Side of Colchicine[J].J Investig Med High Impact Case Rep,2021,9:23247096211029744.[7]Sriranganathan MK,Vinik O,Pardo Pardo J,et al.Interventions for tophi in gout[J].Cochrane Database Syst Rev,2021,8(8):CD010069.[8]Liu CW,Chang WC,Lee CC,et al.The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia-A systematic review and meta-analysis[J].Nutr Metab Cardiovasc Dis,2019,29(10):1011-1022.[9]Neogi T,Jansen TL,Dalbeth N,et al.2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J].Ann Rheum Dis,2015,74(10):1789-1798. [10]Matsushita K,Mahmoodi BK,Woodward M,et al.Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate[J].JAMA,2012,307(18):1941-1951.[11]Yin R,Li L,Zhang G,et al.Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis[J].BMJ Open,2018,8(4):e017542. [12]Medani S,Wall C.Colchicine toxicity in renal patients-Are we paying attention?[J].Clin Nephrol,2016,86(2):100-105. [13]Alkadi H,Khubeiz MJ,Jbeily R.Colchicine: A Review on Chemical Structure and Clinical Usage[J].Infect Disord Drug Targets,2018,18(2):105-121.[14]Vargas-Santos AB,Neogi T.Management of Gout and Hyperuricemia in CKD[J].Am J Kidney Dis,2017,70(3):422-439.[15]Zhu Y,Pandya BJ,Choi HK.Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008[J].Am J Med,2012,125:679-687. [16]Krishnan E.Reduced glomerular function and prevalence of gout: NHANES 2009-2010[J].PLoS One,2012,7:e50046. [17]Saag KG,Becker MA,Whelton A,et al.Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study[J].Arthritis Rheumatol,2019,71(1):143-153. [18]Gunawardhana L,Becker MA,Whelton A,et al.Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment:phase II placebo-controlled study[J].Arthritis Res Ther,2018,20(1):99. [19]Yang AY.Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases[J].Int J Clin Pharmacol Ther,2020,58(1):21-28.[20]Hu AM,Brown JN.Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review[J].Clin Rheumatol,2020,39(11):3287-3294.[21]Chou HW,Chiu HT,Tsai CW,et al.Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study[J].Nephrol Dial Transplant,2018,33(9):1620-1627. [22]Liu X,Wang H,Ma R,et al.The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5[J].Clin Exp Nephrol,2019,23(3):362-370.[23]Liang N,Sun M,Sun R,et al.Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort[J].Arthritis Res Ther,2019,21(1):200. [24]Yamanaka H,Tamaki S,Ide Y,et al.Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study[J].Ann Rheum Dis,2018,77(2):270-276.

相似文献/References:

[1]刘 星,刘璟琰,张思宇.维生素C联合非布司他对高尿酸血症伴痛风患者sICAM-1及尿酸的影响[J].医学信息,2020,33(07):87.[doi:10.3969/j.issn.1006-1959.2020.07.024]
 LIU Xing,LIU Jing-yan,ZHANG Si-yu.Effects of Vitamin C Combined with Febuxostat on sICAM-1 and Uric Acid in Patients with Hyperuricemia and Gout[J].Journal of Medical Information,2020,33(18):87.[doi:10.3969/j.issn.1006-1959.2020.07.024]
[2]倪 曼.非布司他与别嘌醇治疗慢性肾脏病合并高尿酸血症的疗效比较[J].医学信息,2020,33(15):140.[doi:10.3969/j.issn.1006-1959.2020.15.043]
 NI Man.Comparison of the Efficacy of Febuxostat Tablets and Allopurinol in the Treatment of Chronic Kidney Disease with Hyperuricemia[J].Journal of Medical Information,2020,33(18):140.[doi:10.3969/j.issn.1006-1959.2020.15.043]
[3]李凤敏,顾玲玲,付建茹.非布司他与别嘌醇治疗高尿酸血症伴痛风的疗效比较[J].医学信息,2022,35(01):165.[doi:10.3969/j.issn.1006-1959.2022.01.041]
 LI Feng-min,GU Ling-ling,FU Jian-ru.Comparison of Febuxostat and Allopurinol in the Treatment of Hyperuricemia with Gout[J].Journal of Medical Information,2022,35(18):165.[doi:10.3969/j.issn.1006-1959.2022.01.041]

更新日期/Last Update: 1900-01-01